Yuming Zhu

机构：Third People 's Hospital of Chongqing, Chongqing Medical University · ORCID：0000-0002-4833-4240

发表论文 172 篇 · 总被引 3226 次 · h-index 31

代表论文

• Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies (2024 · Cell · 被引 191)
• Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II–III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory study (2024 · Signal Transduction and Targeted Therapy · 被引 36)
• Neoadjuvant Aumolertinib for unresectable stage III EGFR-mutant non-small cell lung cancer: a single-arm phase II trial (2025 · Nature Communications · 被引 15)
• Fe2O3 Hollow Multishelled Structure Endowed Temporal Sequential Mass Release for Apoptosis/Ferroptosis‐Induced Combined Cancer Therapy (2025 · Advanced Functional Materials · 被引 8)
• Selective inhibition of TGF-β-induced epithelial-mesenchymal transition overcomes chemotherapy resistance in high-risk lung squamous cell carcinoma (2025 · Communications Biology · 被引 7)
• Neoadjuvant camrelizumab plus chemotherapy or apatinib for resectable stage IIA–IIIA NSCLC: a multicenter, two-arm, phase II exploratory trial (2025 · BMC Medicine · 被引 6)